Share this article Share this article ResearchAndMarkets.com's offering. This report features an extensive study of the current market landscape and the future potential of sterile fill/finish services for small molecule drugs. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Small molecule drugs account for nearly 90% of the contemporary therapeutics pipeline. In fact, in 2019, the FDA's Center for Drug Evaluation and Research approved 48 small molecule drugs, representing 70% of the new molecular entities (NMEs) clearing regulat...